{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:21Z","timestamp":1787023281189,"version":"build-2736575974"},"reference-count":197,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.<\/jats:p>","DOI":"10.1634\/theoncologist.6-2-162","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T17:38:39Z","timestamp":1093369119000},"page":"162-176","source":"Crossref","is-referenced-by-count":355,"title":["Hepatotoxicity of Chemotherapy"],"prefix":"10.1093","volume":"6","author":[{"given":"Paul D.","family":"King","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri-Columbia, Columbia, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Perry","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, Department of Internal Medicine, University of Missouri-Columbia, Columbia, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2001,4,1]]},"reference":[{"key":"2021122210154230700_R1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0889-8553(21)00227-2","article-title":"Morphologic spectrums of drug-induced liver disease","volume":"24","author":"Ishak","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"key":"2021122210154230700_R2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","article-title":"Criteria of drug-induced liver disorders: report of an international consensus meeting","volume":"11","author":"Benichou","year":"1990","journal-title":"J Hepatol"},{"key":"2021122210154230700_R3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510260319","article-title":"Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis","volume":"26","author":"Maria","year":"1997","journal-title":"Hepatology"},{"key":"2021122210154230700_R4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","article-title":"Evaluation of abnormal liver enzyme results in asymptomatic patients","volume":"342","author":"Pratt","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122210154230700_R5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199510263331706","article-title":"Drug-induced hepatotoxicity","volume":"333","author":"Lee","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122210154230700_R6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-8278(97)80498-9","article-title":"Drug elimination in chronic liver diseases","volume":"2","author":"Huet","year":"1997","journal-title":"J Hepatol"},{"key":"2021122210154230700_R7","first-page":"1098","article-title":"Antecedent liver disease and drug toxicity","volume":"31","author":"Shenker","year":"1999","journal-title":"J Hepatol"},{"key":"2021122210154230700_R8","first-page":"551","article-title":"Chemotherapeutic agents and hepatotoxicity","volume":"19","author":"Perry","year":"1992","journal-title":"Semin Oncol"},{"key":"2021122210154230700_R9","first-page":"673","volume-title":"ed. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver","author":"Zimmerman","year":"1999","edition":"2nd Edition"},{"key":"2021122210154230700_R10","article-title":"Drug-Induced Liver Disease","volume-title":"New York: Churchill Livingstone, 1994.","author":"Farrell"},{"key":"2021122210154230700_R11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/106002809202600311","article-title":"The effects of impaired liver function on the elimination of antineoplastic agents","volume":"26","author":"Koren","year":"1992","journal-title":"Ann Pharmacother"},{"key":"2021122210154230700_R12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-2008-1040580","article-title":"Hepatic toxicity of drugs used for hematologic neoplasia","volume":"7","author":"Sznol","year":"1987","journal-title":"Semin Liver Dis"},{"key":"2021122210154230700_R13","first-page":"250","article-title":"Intestinal and liver toxicity of antineoplastic drugs","volume":"140","author":"McDonald","year":"1984","journal-title":"West J Med"},{"key":"2021122210154230700_R14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0016-5085(80)90205-X","article-title":"Antineoplastic agents and the liver","volume":"78","author":"Menard","year":"1980","journal-title":"Gastroenterology"},{"key":"2021122210154230700_R15","first-page":"36","article-title":"Drug induced liver disease: pathogenetic mechanisms and histopathological lesions","volume":"2","author":"DeSmet","year":"1993","journal-title":"Eur J Med"},{"key":"2021122210154230700_R16","volume-title":"Cancer Chemotherapy and Biotherapy: Principles and Practice","author":"Chabner","year":"1996","edition":"Second edition"},{"key":"2021122210154230700_R17","article-title":"Principles of antineoplastic drug development and pharmacology","volume-title":"New York: Marcel Dekker, 1996.","author":"Schilsky"},{"key":"2021122210154230700_R18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/bmj.3.5722.588","article-title":"Massive hepatic necrosis after cyclophosphamide","volume":"3","author":"Aubrey","year":"1970","journal-title":"Br Med J"},{"key":"2021122210154230700_R19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.5694\/j.1326-5377.1972.tb103722.x","article-title":"Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide","volume":"2","author":"Walters","year":"1972","journal-title":"Med J Aust"},{"key":"2021122210154230700_R20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.7326\/0003-4819-97-1-62","article-title":"Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus","volume":"97","author":"Bacon","year":"1982","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00007611-198502000-00034","article-title":"Cyclophosphamide associated hepatotoxicity","volume":"78","author":"Goldberg","year":"1985","journal-title":"South Med J"},{"key":"2021122210154230700_R22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0025-6196(12)60074-3","article-title":"Cyclophosphamide induced hepatotoxicity in a patient with Wegener's granulomatosis","volume":"68","author":"Snyder","year":"1993","journal-title":"Mayo Clin Proc"},{"key":"2021122210154230700_R23","first-page":"309","article-title":"Cyclophosphamide induced liver necrosis: a possible interaction with azathioprine","volume":"252","author":"Shaunak","year":"1988","journal-title":"Q J Med, New Series"},{"key":"2021122210154230700_R24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.1983.1.6.359","article-title":"Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation in the treatment of refractory cancer","volume":"1","author":"Lazarus","year":"1983","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1200\/JCO.1986.4.11.1586","article-title":"Phase II trial of high dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma","volume":"4","author":"Leff","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0016-5085(62)80049-3","article-title":"Liver damage after chemotherapy for leukemia and lymphoma","volume":"42","author":"Amromin","year":"1962","journal-title":"Gastroenterology"},{"key":"2021122210154230700_R27","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jama.1958.72990200007007c","article-title":"Hepatotoxicity due to chlorambucil. Report of a case","volume":"167","author":"Koler","year":"1958","journal-title":"JAMA"},{"key":"2021122210154230700_R28","first-page":"682","article-title":"Busulfan induced hepatitis","volume":"83","author":"Morris","year":"1988","journal-title":"Am J Gastroenterol"},{"key":"2021122210154230700_R29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.1.5748.556-b","article-title":"Jaundice after treatment of leukemia with busulfan","volume":"1","author":"Underwood","year":"1971","journal-title":"Br Med J"},{"key":"2021122210154230700_R30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0006-2952(83)90451-3","article-title":"Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3 chloroethyl-nitrosurea (BCNU)","volume":"32","author":"Meredith","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"2021122210154230700_R31","first-page":"1876","article-title":"Clinical trials with 1,3-bis (2-chloroethyl)-nitrosourea, NSC-409962","volume":"25","author":"Vita","year":"1965","journal-title":"Cancer Res"},{"key":"2021122210154230700_R32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1097-0142(197307)32:1<38::AID-CNCR2820320105>3.0.CO;2-I","article-title":"CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer","volume":"32","author":"Hoogstraten","year":"1973","journal-title":"Cancer"},{"key":"2021122210154230700_R33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"Pancreatic islet cell carcinoma II: results of therapy with streptozotocin in 52 patients","volume":"79","author":"Broder","year":"1973","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/1097-0142(197410)34:4<993::AID-CNCR2820340404>3.0.CO;2-T","article-title":"Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)","volume":"34","author":"Schein","year":"1974","journal-title":"Cancer"},{"key":"2021122210154230700_R35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V32.4.507.507","article-title":"Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults","volume":"32","author":"Ellison","year":"1968","journal-title":"Blood"},{"key":"2021122210154230700_R36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mpo.2950110416","article-title":"Cytosine arabinoside induced liver damage: histopathologic demonstration","volume":"11","author":"Pizzuto","year":"1983","journal-title":"Med Pediatr Oncol"},{"key":"2021122210154230700_R37","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/1097-0142(19841201)54:11<2360::AID-CNCR2820541109>3.0.CO;2-D","article-title":"Hepatic dysfunction and jaundice following high-dose cytosine arabinoside","volume":"54","author":"George","year":"1984","journal-title":"Cancer"},{"key":"2021122210154230700_R38","first-page":"1059","article-title":"Pharmacology and toxicity of high dose cytarabine by 72-hour continuous infusion","volume":"70","author":"Donehower","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R39","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-82-5-684","article-title":"Cytabarine","volume":"82","author":"Kremer","year":"1975","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0002-9343(86)90287-1","article-title":"Clinical studies: phase I II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia","volume":"81","author":"Kantarjian","year":"1986","journal-title":"Am J Med"},{"key":"2021122210154230700_R41","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/1097-0142(1971)28:4<907::AID-CNCR2820280414>3.0.CO;2-9","article-title":"5-Fluorouracil given once weekly: comparison of intravenous and oral administration","volume":"28","author":"Bateman","year":"1971","journal-title":"Cancer"},{"key":"2021122210154230700_R42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1200\/JCO.1985.3.1.98","article-title":"Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine","volume":"3","author":"Hohn","year":"1985","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R43","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/1097-0142(19860815)58:4<855::AID-CNCR2820580409>3.0.CO;2-6","article-title":"Liver pathology following hepatic arterial infusion chemotherapy: hepatic toxicity with FUDR","volume":"58","author":"Doria","year":"1986","journal-title":"Cancer"},{"key":"2021122210154230700_R44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7326\/0003-4819-107-4-459","article-title":"Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma","volume":"107","author":"Kemeny","year":"1987","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00000658-198712000-00001","article-title":"A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases","volume":"206","author":"Chang","year":"1987","journal-title":"Ann Surg"},{"key":"2021122210154230700_R46","first-page":"1162","article-title":"Fatal liver cirrhosis associated with long term arterial infusion of floxuridine","volume-title":"Lancet","author":"Pettavel","year":"1986"},{"key":"2021122210154230700_R47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.1985.3.2.161","article-title":"Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump","volume":"3","author":"Shepard","year":"1985","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R48","first-page":"1","article-title":"Status of infusion chemotherapy for the treatment of liver metastases","volume":"3","author":"Niederhuber","year":"1989","journal-title":"Princ Pract Oncol Updates"},{"key":"2021122210154230700_R49","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.1989.7.11.1646","article-title":"A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial","volume":"7","author":"Hohn","year":"1989","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R50","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archsurg.1990.01410200086013","article-title":"Intra arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial","volume":"125","author":"Martin","year":"1990","journal-title":"Arch Surg"},{"key":"2021122210154230700_R51","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jama.1964.03060350028007","article-title":"Hepatotoxicity of mercaptopurine","volume":"188","author":"Einhorn","year":"1964","journal-title":"JAMA"},{"key":"2021122210154230700_R52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archinte.1968.00300060056011","article-title":"Hepatotoxicity of mercaptopurine","volume":"122","author":"Shorey","year":"1968","journal-title":"Arch Intern Med"},{"key":"2021122210154230700_R53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1749-6632.1954.tb40019.x","article-title":"The toxic effects of 6-mercaptopurine and related compounds","volume":"60","author":"Phillips","year":"1957","journal-title":"Ann NY Acad Sci"},{"key":"2021122210154230700_R54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1749-6632.1954.tb40030.x","article-title":"Summary of experience with 6-mercaptopurine","volume":"60","author":"Farber","year":"1954","journal-title":"Ann NY Acad Sci"},{"key":"2021122210154230700_R55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V14.1.80.80","article-title":"Hepatitis in association with prolonged 6-mercaptopurine therapy","volume":"14","author":"McIlvanie","year":"1959","journal-title":"Blood"},{"key":"2021122210154230700_R56","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/bmj.1.5170.393","article-title":"Toxic complications of treatment with 6-mercaptopurine. Two cases with hepatic necrosis and intestinal ulceration","volume":"1","author":"Clark","year":"1960","journal-title":"Br Med J"},{"key":"2021122210154230700_R57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF02897290","article-title":"A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors","volume":"26","author":"Adamson","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122210154230700_R58","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R59","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/0003-4819-79-5-694","article-title":"Azathioprine","volume":"79","author":"Rosman","year":"1973","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/bmj.1.5897.49","article-title":"Treatment of psoriasis with azathioprine","volume":"1","author":"DuVivier","year":"1974","journal-title":"Br Med J"},{"key":"2021122210154230700_R61","first-page":"518","article-title":"Probable azathioprine hepatotoxicity: a case report","volume":"62","author":"Small","year":"1989","journal-title":"Ann Allergy"},{"key":"2021122210154230700_R62","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF01300713","article-title":"Sclerosing hepatitis and azathioprine [letter]","volume":"31","author":"Barrowman","year":"1986","journal-title":"Dig Dis Sci"},{"key":"2021122210154230700_R63","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-85-5-578","article-title":"Veno-occlusive disease of the liver after chemotherapy of acute leukemia","volume":"85","author":"Griner","year":"1976","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R64","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/jcp.35.10.1086","article-title":"6-thioguanine as a cause of toxic veno-occlusive disease of the liver","volume":"35","author":"Satti","year":"1982","journal-title":"J Clin Pathol"},{"key":"2021122210154230700_R65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-96-1-58","article-title":"Hepatic veno-occlusive disease caused by 6-thioguanine","volume":"96","author":"Gill","year":"1982","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R66","doi-asserted-by":"crossref","first-page":"788","DOI":"10.7326\/0003-4819-96-6-788_1","article-title":"Reversible hepatic veno-occlusive disease and 6 thioguanine [letter]","volume":"96","author":"Krivoy","year":"1982","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R67","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.29.9.1265","article-title":"Case report: peliosis hepatis induced by 6-thioguanine administration","volume":"29","author":"Larrey","year":"1988","journal-title":"Gut"},{"key":"2021122210154230700_R68","first-page":"139","article-title":"Evaluation of two antineoplastic agents: pipobroman (Vercyte) and thioguanine","volume":"200","author":"Council on Drugs","year":"1967","journal-title":"JAMA"},{"key":"2021122210154230700_R69","first-page":"811","article-title":"Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC 740) in man","volume":"59","author":"Leme","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"2021122210154230700_R70","first-page":"198","article-title":"Hepatic fibrosis in children with acute leukemia\u2003after therapy with folic acid antagonists","volume":"59","author":"Colsky","year":"1955","journal-title":"Arch Pathol Lab Med"},{"key":"2021122210154230700_R71","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0022-3476(77)80587-8","article-title":"Methotrexate hepatotoxicity in children with leukemia","volume":"90","author":"McIntosh","year":"1977","journal-title":"J Pediatr"},{"key":"2021122210154230700_R72","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/1097-0142(196003\/04)13:2<288::AID-CNCR2820130213>3.0.CO;2-L","article-title":"Hepatic fibrosis in children with acute leukemia: a complication of therapy","volume":"13","author":"Hutter","year":"1960","journal-title":"Cancer"},{"key":"2021122210154230700_R73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0090-8258(86)90123-X","article-title":"Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease","volume":"23","author":"Berkowitz","year":"1986","journal-title":"Gynecol Oncol"},{"key":"2021122210154230700_R74","first-page":"207","article-title":"Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood","volume":"5","author":"Weber","year":"1987","journal-title":"NCI Monogr"},{"key":"2021122210154230700_R75","first-page":"787","article-title":"Liver injury associated with methotrexate therapy for psoriasis","volume":"48","author":"Podurgiel","year":"1973","journal-title":"Mayo Clin Proc"},{"key":"2021122210154230700_R76","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3949\/ccjm.52.2.129","article-title":"Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis","volume":"52","author":"MacKenzie","year":"1985","journal-title":"Cleve Clin Q"},{"key":"2021122210154230700_R77","first-page":"29","article-title":"Methotrexate and the liver","volume":"12","author":"Tolman","year":"1985","journal-title":"J Rheumatol"},{"key":"2021122210154230700_R78","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2133.1975.tb06498.x","article-title":"A prospective study of the effects of weekly oral methotrexate on liver biopsy","volume":"93","author":"Warin","year":"1975","journal-title":"Br J Dermatol"},{"key":"2021122210154230700_R79","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1001\/jama.1977.03280250057025","article-title":"Hepatoma in a child with methotrexate induced hepatic fibrosis","volume":"238","author":"Ruymann","year":"1977","journal-title":"JAMA"},{"key":"2021122210154230700_R80","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1002\/1097-0142(19871115)60:10<2548::AID-CNCR2820601033>3.0.CO;2-H","article-title":"Hepatocellular carcinoma in a long term survivor of acute lymphocytic leukemia","volume":"60","author":"Fried","year":"1987","journal-title":"Cancer"},{"key":"2021122210154230700_R81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M","article-title":"Adriamycin chemotherapy. Efficacy, safety, and pharmacologic basis of an intermittent single high dose schedule","volume":"33","author":"Benjamin","year":"1974","journal-title":"Cancer"},{"key":"2021122210154230700_R82","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00001813-199803000-00001","article-title":"Gemcitabine\u2014a safety review","volume":"9","author":"Aapro","year":"1998","journal-title":"Anticancer Drugs"},{"key":"2021122210154230700_R83","first-page":"912","article-title":"Hepatic injury during doxorubicin therapy","volume":"108","author":"Aviles","year":"1984","journal-title":"Arch Pathol Lab Med"},{"key":"2021122210154230700_R84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","article-title":"Mitoxantrone: a new anticancer drug with significant clinical activity","volume":"105","author":"Shenkenberg","year":"1986","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R85","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-105-5-805_3","article-title":"Mitoxantrone and hepatic toxicity [letter]","volume":"105","author":"Paciucci","year":"1986","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R86","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N","article-title":"A clinical review of bleomycin. A new antineoplastic agent","volume":"31","author":"Blum","year":"1973","journal-title":"Cancer"},{"key":"2021122210154230700_R87","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0305-7372(76)80019-9","article-title":"Mitomycin C: a review","volume":"3","author":"Crooke","year":"1976","journal-title":"Cancer Treat Rev"},{"key":"2021122210154230700_R88","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000196858","article-title":"Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice","volume":"1","author":"Robert","year":"1968","journal-title":"Digestion"},{"key":"2021122210154230700_R89","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM196501212720301","article-title":"Mithramycin in the treatment of disseminated testicular neoplasms","volume":"272","author":"Brown","year":"1965","journal-title":"N Engl J Med"},{"key":"2021122210154230700_R90","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0002-9343(70)80044-4","article-title":"Metabolic and toxic effects of mithramycin during tumor therapy","volume":"49","author":"Kennedy","year":"1970","journal-title":"Am J Med"},{"key":"2021122210154230700_R91","first-page":"1779","article-title":"A comparison of the rate of recovery from inhibition of RNA synthesis in mouse liver and transplantable glioma","volume":"27","author":"Yarbro","year":"1967","journal-title":"Cancer Res"},{"key":"2021122210154230700_R92","first-page":"1379","article-title":"Hepatic toxicity of low doses of mithramycin in hypercalcemia","volume":"68","author":"Green","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R93","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2214\/ajr.106.4.750","article-title":"Liver irradiation in children: acute changes with transient leukopenia and thrombocytopenia","volume":"106","author":"Tefft","year":"1969","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"2021122210154230700_R94","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/(SICI)1096-911X(199911)33:5<462::AID-MPO5>3.0.CO;2-8","article-title":"Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9\/GPOH","volume":"33","author":"Ludwig","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"2021122210154230700_R95","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(89)91192-6","article-title":"Hepatotoxicity of actinomycin-D","volume":"1","author":"Pritchard","year":"1989","journal-title":"Lancet"},{"key":"2021122210154230700_R96","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F","article-title":"Hepatotoxicity following vincristine therapy","volume":"54","author":"El Saghir","year":"1984","journal-title":"Cancer"},{"key":"2021122210154230700_R97","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00255486","article-title":"Can severe vincristine neurotoxicity be prevented?","volume":"8","author":"Desai","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122210154230700_R98","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/07357909509031919","article-title":"Taxanes: a new class of antitumor agents","volume":"13","author":"Huizing","year":"1995","journal-title":"Cancer Invest"},{"key":"2021122210154230700_R99","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0305-7372(79)80045-6","article-title":"Etoposide (VP-16)","volume":"6","author":"Issell","year":"1979","journal-title":"Cancer Treat Rev"},{"key":"2021122210154230700_R100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0168-8278(91)90905-Q","article-title":"Etoposide (VP-213) induced hepatitis. Report of three cases following standard-dose treatments","volume":"12","author":"Tran","year":"1991","journal-title":"J Hepatol"},{"key":"2021122210154230700_R101","first-page":"1023","article-title":"Etoposide induced hepatic injury: a potential complication of high-dose therapy","volume":"67","author":"Johnson","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R102","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00570500","article-title":"Highdose VP-16 with intermediate dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia","volume":"20","author":"Chan","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122210154230700_R103","first-page":"1247","article-title":"Phase II studies of dianhydrogalactitol and VP-213","volume":"60","author":"Perry","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0889-8588(18)30176-X","article-title":"Topoisomerase inhibitors","volume":"8","author":"Burris","year":"1994","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122210154230700_R105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0305-7372(94)90011-6","article-title":"Topoisomersase I inhibitors: topotecan and irinotecan","volume":"20","author":"Creemers","year":"1994","journal-title":"Cancer Treat Rev"},{"key":"2021122210154230700_R106","first-page":"2125","article-title":"A case of liver toxicity following cis-diammine dichloroplatinum (II) treatment","volume":"62","author":"Cavalli","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R107","first-page":"647","article-title":"Clinical studies of platinum coordination compounds in the treatment of various malignant diseases","volume":"59","author":"Hill","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"2021122210154230700_R108","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.1987.5.2.318","article-title":"Cisplatin-induced hepatic toxicity [letter]","volume":"5","author":"Pollera","year":"1987","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R109","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/07357909109021323","article-title":"Fatal thrombocytopenia and liver failure associated with carboplatin therapy","volume":"9","author":"Hruban","year":"1991","journal-title":"Cancer Invest"},{"key":"2021122210154230700_R110","volume-title":"gross hematuria b. hepatic veno-occlusive disease","author":"Christian","year":"1989"},{"key":"2021122210154230700_R111","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJM196911062811902","article-title":"L-Asparaginase: therapeutic and toxic effects in patients with neoplastic disease","volume":"281","author":"Haskell","year":"1969","journal-title":"N Engl J Med"},{"key":"2021122210154230700_R112","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev.me.21.020170.002245","article-title":"L-Asparaginase","volume":"21","author":"Capizzi","year":"1970","journal-title":"Annu Rev Med"},{"key":"2021122210154230700_R113","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U","article-title":"Toxicity of E. coli L-asparaginase in man","volume":"25","author":"Oettgen","year":"1970","journal-title":"Cancer"},{"key":"2021122210154230700_R114","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00216938","article-title":"A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkin's lymphomas","volume":"8","author":"Muss","year":"1990","journal-title":"Invest New Drugs"},{"key":"2021122210154230700_R115","first-page":"349","volume-title":"Cancer: Principles and Practice of Oncology","author":"Chabner","year":"1989","edition":"3rd ed"},{"key":"2021122210154230700_R116","first-page":"61","article-title":"Drug-induced granulomatous hepatitis","volume":"44","author":"McMaster","year":"1981","journal-title":"Lab Invest"},{"key":"2021122210154230700_R117","first-page":"103","article-title":"A phase I study of hydroxyurea","volume":"29","author":"Thurman","year":"1963","journal-title":"Cancer Chemother Rep"},{"key":"2021122210154230700_R118","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5694\/j.1326-5377.1980.tb134684.x","article-title":"Hydroxyurea induced hepatitis","volume":"1","author":"Heddle","year":"1980","journal-title":"Med J Aust"},{"key":"2021122210154230700_R119","first-page":"219","article-title":"Allergy-induced hepatic toxicity associated with dacarbazine [letter]","volume":"71","author":"McClay","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jso.2930270415","article-title":"Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma","volume":"27","author":"Erichsen","year":"1984","journal-title":"J Surg Oncol"},{"key":"2021122210154230700_R121","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1002\/1097-0142(19800515)45:10<2670::AID-CNCR2820451031>3.0.CO;2-L","article-title":"Hepatic veno-occlusive disease due to DTIC","volume":"45","author":"Asbury","year":"1980","journal-title":"Cancer"},{"key":"2021122210154230700_R122","first-page":"813","article-title":"Phase I-II trial of lymphoblastoid interferon in metastatic malignant melanoma","volume":"69","author":"Goldberg","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R123","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/bmj.282.6278.1744","article-title":"Hepatic vascular lesions associated with dacarbazine treatment","volume":"282","author":"Greenstone","year":"1981","journal-title":"Br Med J"},{"key":"2021122210154230700_R124","first-page":"336","article-title":"Interferons in the treatment of human cancer","volume":"4","author":"Kirkwood","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R125","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity of interferons in cancer patients","volume":"4","author":"Quesada","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R126","first-page":"263","article-title":"Clinical and phase I-II studies: treatment of renal cell carcinoma with alpha (human leucocyte) interferon and vinblastine in combination","volume":"69","author":"Figlin","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R127","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/0016-5085(95)90139-6","article-title":"Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C","volume":"108","author":"Garcia-Buey","year":"1995","journal-title":"Gastroenterology"},{"key":"2021122210154230700_R128","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1200\/JCO.1989.7.12.1852","article-title":"Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients","volume":"7","author":"Fisher","year":"1989","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R129","first-page":"507","article-title":"Mechanisms of interleukin-2 induced hepatic toxicity","volume":"56","author":"Nakagawa","year":"1996","journal-title":"Cancer Res"},{"key":"2021122210154230700_R130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0002-9343(50)90065-9","article-title":"Jaundice during methyl testosterone therapy","volume":"8","author":"Werner","year":"1950","journal-title":"Am J Med"},{"key":"2021122210154230700_R131","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM197105202842006","article-title":"Hepatoma and peliosis hepatitis in Fanconi's anemia","volume":"284","author":"Bernstein","year":"1971","journal-title":"N Engl J Med"},{"key":"2021122210154230700_R132","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0140-6736(73)91384-6","article-title":"Androgenic-anabolic steroid therapy and hepatocellular carcinoma","volume":"1","author":"Henderson","year":"1973","journal-title":"Lancet"},{"key":"2021122210154230700_R133","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/BF01303188","article-title":"Cholestatic hepatitis following flutamide","volume":"38","author":"Rosman","year":"1993","journal-title":"Dig Dis Sci"},{"key":"2021122210154230700_R134","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1097-0142(19890201)63:3<438::AID-CNCR2820630307>3.0.CO;2-O","article-title":"Jaundice and intrahepatic cholestasis following high dose megestrol acetate for breast cancer","volume":"63","author":"Foitl","year":"1989","journal-title":"Cancer"},{"key":"2021122210154230700_R135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0168-8278(95)80316-5","article-title":"Tamoxifen associated steatohepatitis report of 3 cases","volume":"23","author":"Pinto","year":"1995","journal-title":"J Hepatol"},{"key":"2021122210154230700_R136","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(86)90266-4","article-title":"Hepatic veno-occlusive disease","volume":"81","author":"Rollins","year":"1986","journal-title":"Am J Med"},{"key":"2021122210154230700_R137","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/07357909509031914","article-title":"Abnormal liver function in patients undergoing autologous bone marrow transplantation for hematological malignancies","volume":"13","author":"Wasserheit","year":"1995","journal-title":"Cancer Invest"},{"key":"2021122210154230700_R138","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","article-title":"Veno-occlusive disease of the liver after hemopoietic cell transplantation","volume":"64","author":"Carreras","year":"2000","journal-title":"Eur J Haematol"},{"key":"2021122210154230700_R139","doi-asserted-by":"crossref","first-page":"575","DOI":"10.7326\/0003-4819-88-4-575_2","article-title":"Hepatic vein thrombosis after chemotherapy for histiocytoma [letter]","volume":"88","author":"Lehrner","year":"1978","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R140","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.1990.8.10.1699","article-title":"Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas","volume":"8","author":"Ayash","year":"1990","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R141","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-112-11-881_1","article-title":"Busulfan and veno-occlusive disease of the liver","volume":"112","author":"Vassal","year":"1990","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R142","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/0016-5085(80)90911-7","article-title":"An analysis of hepatic veno occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation","volume":"79","author":"Shulman","year":"1980","journal-title":"Gastroenterology"},{"key":"2021122210154230700_R143","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0046-8177(82)80008-7","article-title":"Hepatic veno-occlusive disease after high-dose mitomycin and autologous bone marrow transplantation","volume":"13","author":"Gottfried","year":"1982","journal-title":"Hum Pathol"},{"key":"2021122210154230700_R144","first-page":"119","article-title":"High-dose alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute\/Beth Israel Hospital experience","volume":"71","author":"Antman","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122210154230700_R146","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/BF00257448","article-title":"Pharmacokinetics of high-dose busulfan in children","volume":"24","author":"Vassal","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122210154230700_R147","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/0016-5085(80)90911-7","article-title":"An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation","volume":"79","author":"Shulman","year":"1980","journal-title":"Gastroenterology"},{"key":"2021122210154230700_R148","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1002\/1097-0142(19880515)61:10<1988::AID-CNCR2820611010>3.0.CO;2-5","article-title":"Fatal hepatic vascular toxicity of DTIC","volume":"61","author":"Ceci","year":"1988","journal-title":"Cancer"},{"key":"2021122210154230700_R149","first-page":"321","article-title":"Hepatic toxicity of DTIC","volume":"65","author":"Sutherland","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R150","first-page":"779","article-title":"Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment","volume":"67","author":"Lacroix","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R151","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7326\/0003-4819-104-5-651","article-title":"Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy","volume":"104","author":"Read","year":"1986","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R152","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/1097-0142(19861001)58:7<1437::AID-CNCR2820580710>3.0.CO;2-A","article-title":"Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease","volume":"58","author":"Joensuu","year":"1986","journal-title":"Cancer"},{"key":"2021122210154230700_R153","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/1097-0142(197912)44:6<2324::AID-CNCR2820440648>3.0.CO;2-8","article-title":"Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease","volume":"44","author":"Houghton","year":"1979","journal-title":"Cancer"},{"key":"2021122210154230700_R154","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ajcp\/75.4.614","article-title":"Fatal veno-occlusive disease of the liver following high-dose 1,3-bis (2-chloroethyl)-nitrosourea (BCNU) and autologous bone marrow transplantation","volume":"75","author":"McIntyre","year":"1981","journal-title":"Am J Clin Pathol"},{"key":"2021122210154230700_R155","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/1097-0142(19820501)49:9<1789::AID-CNCR2820490910>3.0.CO;2-H","article-title":"Veno-occlusive disease of the liver after high dose mitomycin C therapy and autologous bone marrow transplantation","volume":"49","author":"Lazarus","year":"1982","journal-title":"Cancer"},{"key":"2021122210154230700_R156","first-page":"369","article-title":"Pathology of the liver with bone marrow transplantation","volume":"99","author":"Beschorner","year":"1980","journal-title":"Am J Pathol"},{"key":"2021122210154230700_R157","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0002-9343(80)90368-X","article-title":"Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation","volume":"68","author":"Woods","year":"1980","journal-title":"Am J Med"},{"key":"2021122210154230700_R158","first-page":"154a","article-title":"Hepatic veno-occlusive disease (VOD) in autologous bone marrow transplantation (BMT)","volume":"6","author":"Siegel","year":"1987","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122210154230700_R159","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/1097-0142(19881001)62:7<1275::AID-CNCR2820620705>3.0.CO;2-I","article-title":"Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide","volume":"62","author":"Teicher","year":"1988","journal-title":"Cancer"},{"key":"2021122210154230700_R160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1991.9.2.268","article-title":"Hepatopathy-thrombocytopenia syndrome: a complication of dactinomycin therapy for Wilms' tumor. A report from the United Kingdom Children's Cancer Study Group","volume":"9","author":"Raine","year":"1991","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R161","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.1990.8.9.1525","article-title":"Severe hepatic toxicity after treatment with vincristine and actinomycin D using single or divided dose schedules: a report from the national Wilms' Tumor Study","volume":"8","author":"Green","year":"1990","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R162","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/1097-0142(197610)38:4<1524::AID-CNCR2820380413>3.0.CO;2-W","article-title":"Clinicopathologic correlation of liver damage in patients treated with 6-mercaptopurine and adriamycin","volume":"38","author":"Minow","year":"1976","journal-title":"Cancer"},{"key":"2021122210154230700_R163","first-page":"1050","article-title":"Oesophageal varices associated with busulphan-thioguanine therapy for chronic myeloid leukaemia","volume-title":"Lancet","author":"Key","year":"1987"},{"key":"2021122210154230700_R164","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00005792-198009000-00004","article-title":"Nodular regenerative hyperplasia of the liver in hematological disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with a hypothesis on the pathogenesis","volume":"59","author":"Wanless","year":"1980","journal-title":"Medicine"},{"key":"2021122210154230700_R165","first-page":"1464","article-title":"High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity","volume":"70","author":"Wolff","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R166","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00043426-198324000-00001","article-title":"Hepatic ultrastructure in leukemic children treated with methotrexate and 6-mercaptopurine","volume":"5","author":"Harb","year":"1983","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"2021122210154230700_R167","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mpo.2950070415","article-title":"Hepatotoxicity in the treatment of acute lymphoblastic leukaemia","volume":"7","author":"Topley","year":"1979","journal-title":"Med Pediatr Oncol"},{"key":"2021122210154230700_R168","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/1097-0142(19881015)62:8<1614::AID-CNCR2820620826>3.0.CO;2-U","article-title":"Elevated serum transaminase values during therapy for acute lymphoblastic leukemia correlate with prior blood transfusion","volume":"62","author":"Hetherington","year":"1988","journal-title":"Cancer"},{"key":"2021122210154230700_R169","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/mpo.2950070410","article-title":"Hepatic toxicity of adjuvant chemotherapy for carcinoma of the breast","volume":"7","author":"Vaughan","year":"1979","journal-title":"Med Pediatr Oncol"},{"key":"2021122210154230700_R170","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1001\/jama.1986.03380210084030","article-title":"Subclinical hepatic toxicity during chemotherapy for breast cancer","volume":"256","author":"Larroquette","year":"1986","journal-title":"JAMA"},{"key":"2021122210154230700_R171","first-page":"377","article-title":"Drug hepatitis of cholestatic type in association with a FAC-regimen for breast cancer","volume":"44","author":"Patakfalvi","year":"1987","journal-title":"Acta Med Hung"},{"key":"2021122210154230700_R172","first-page":"58","article-title":"Hepar lobatum associated with chemotherapy and metastatic breast cancer","volume":"111","author":"Qizilbash","year":"1987","journal-title":"Arch Pathol Lab Med"},{"key":"2021122210154230700_R173","first-page":"6437","article-title":"Phase I trial of hepatic artery infusion of 5-deoxyuridine and 5 fluorouracil in patients with advanced hepatic malignancy: biochemically based chemotherapy","volume":"49","author":"Remick","year":"1989","journal-title":"Cancer Res"},{"key":"2021122210154230700_R174","first-page":"129","article-title":"Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study","volume":"69","author":"McCracken","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R175","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-115-12-946","article-title":"A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N Phosphonacetyl-aspartate (PALA)","volume":"115","author":"Kemeny","year":"1991","journal-title":"Ann Intern Med"},{"key":"2021122210154230700_R176","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.1993.11.12.2386","article-title":"Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy","volume":"11","author":"Moertel","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122210154230700_R177","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/1097-0142(19950515)75:10<2592::AID-CNCR2820751029>3.0.CO;2-G","article-title":"Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil","volume":"75","author":"Sorenson","year":"1995","journal-title":"Cancer"},{"key":"2021122210154230700_R178","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0954-6820.1982.tb03192.x","article-title":"Fatal hepatitis following irradiation and vincristine","volume":"212","author":"Hansen","year":"1982","journal-title":"Acta Med Scand"},{"key":"2021122210154230700_R179","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/1097-0142(197807)42:1<81::AID-CNCR2820420113>3.0.CO;2-K","article-title":"Hepatopathy following irradiation and Adriamycin","volume":"42","author":"Kun","year":"1978","journal-title":"Cancer"},{"key":"2021122210154230700_R180","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archsurg.1968.01330240024006","article-title":"Radiation hepatitis","volume":"96","author":"Lansing","year":"1968","journal-title":"Arch Surg"},{"key":"2021122210154230700_R181","first-page":"1023","article-title":"Fatal necrosis after high-dose chemotherapy following haloalkane anesthesia","volume":"64","author":"Spiegel","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"2021122210154230700_R182","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1445-5994.1984.tb03591.x","article-title":"Fulminant hepatic failure due to allopurinol","volume":"14","author":"Raper","year":"1984","journal-title":"NZ Med J"},{"key":"2021122210154230700_R183","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/106002808501900606","article-title":"Hepatitis associated with allopurinol","volume":"19","author":"Ohsawa","year":"1985","journal-title":"Drug Intell Clin Pharm"},{"key":"2021122210154230700_R184","first-page":"1745","article-title":"Allopurinol hepatotoxicity potentiated by tamoxifen","volume-title":"NY State J Med","author":"Shah","year":"1982"},{"key":"2021122210154230700_R185","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/bmj.283.6295.825","article-title":"Toxic hepatitis during ketoconazole treatment","volume":"283","author":"Heiberg","year":"1981","journal-title":"Br Med J"},{"key":"2021122210154230700_R186","first-page":"1058","article-title":"Hepatitis and ketoconazole therapy","volume":"283","author":"MacNair","year":"1981","journal-title":"Br Med J"},{"key":"2021122210154230700_R187","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/bmj.283.6298.1058-d","article-title":"Hepatitis and ketoconazole therapy [letter]","volume":"283","author":"Firebrace","year":"1981","journal-title":"Br Med J"},{"key":"2021122210154230700_R188","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archinte.1994.00420010136016","article-title":"Evaluation of hepatic injury arising during fluconazole therapy","volume":"154","author":"Trujillo","year":"1994","journal-title":"Arch Intern Med"},{"key":"2021122210154230700_R189","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0140-6736(94)92790-1","article-title":"Jaundice with ondansetron","volume":"344","author":"Verrill","year":"1994","journal-title":"Lancet"},{"key":"2021122210154230700_R190","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jama.1995.03520300063038","article-title":"Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications","volume":"273","author":"Gordon","year":"1995","journal-title":"JAMA"},{"key":"2021122210154230700_R191","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/0140-6736(92)92535-N","article-title":"G-CSF and liver toxicity in a patient with neuroblastoma","volume":"340","author":"Gupnther","year":"1992","journal-title":"Lancet"},{"key":"2021122210154230700_R192","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(93)90173-M","article-title":"Liver damage in patients with colony-stimulating-factor-producing tumors","volume":"94","author":"Suzuki","year":"1993","journal-title":"Am J Med"},{"key":"2021122210154230700_R193","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0002-9343(88)80239-0","article-title":"Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases","volume":"85","author":"Mitchell","year":"1988","journal-title":"Am J Med"},{"key":"2021122210154230700_R194","first-page":"93","volume-title":"A Clinician's Guide to Chemotherapy Pharmokinetics and Pharmacodynamics","author":"Robert","year":"1998"},{"key":"2021122210154230700_R195","volume-title":"Manufacture's insert, Bedford Laboratories"},{"key":"2021122210154230700_R196","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00255486","article-title":"Can severe vincristine neurotoxicity be prevented?","volume":"8","author":"Desai","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122210154230700_R197","first-page":"139","article-title":"Paclitaxel in patients with liver dysfunction","volume":"350","author":"Venook","year":"1994","journal-title":"Proc Amer Soc Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.6-2-162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.6-2-162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/2\/162\/41837708\/oncolo_6_2_162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/2\/162\/41837708\/oncolo_6_2_162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T13:21:47Z","timestamp":1640179307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/6\/2\/162\/6387676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":197,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2001,4,1]]},"published-print":{"date-parts":[[2001,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.6-2-162","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2001,4,1]]},"published":{"date-parts":[[2001,4,1]]}}}